Tegaserod is effective in the retreatment of irritable bowel syndrome with constipation (IBS-C)

Mueller–Lissner, Stefan; Holtmann, Gerald; Loeffler, Helena; Rueegg, Peter

doi:10.1016/s0016-5085(03)82905-0

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from patients receiving tegeserod reveal that up to 85% develop symptomatic recurrence after discontinuing a successful therapeutic course, of whom 80% achieve symptomatic remission following a second therapeutic course. 21 Although these data apply to patients with constipation-predominant IBS (IBS-C), we adopted these favorable results to our hypothetic cohort of IBD-D patients. To bias the model against CS testing, we further assumed that only 50% (instead of 85%) of IBS-D patients developed symptomatic recurrence following successful therapy and adopted the tegaserod data of 80% remission following a second therapeutic course.…”

Section: Model Assumptionsmentioning

confidence: 99%

Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: A cost-effectiveness analysis☆

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Model Assumptionsmentioning

confidence: 99%

Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: A cost-effectiveness analysis☆

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Uncontrolled data suggest that repeated treatment is effective in IBS-C patients responding to initial tegaserod therapy. [5][6][7] The current study was a controlled trial designed to evaluate the efficacy and safety of repeated treatment with tegaserod, and assess the impact of tegaserod on quality of life (QoL) and health economic measures in IBS-C.…”

mentioning

confidence: 99%

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

Tack

Müller-Lissner

Bytzer³

et al. 2005

Gut

150

129

View full text Add to dashboard Cite

Background: It has been proposed that treatments for irritable bowel syndrome with constipation (IBS-C) should provide rapid symptomatic relief, be intermittent, and effective upon repeated use. Aims: To evaluate the efficacy and safety of tegaserod on IBS symptoms, and its impact on quality of life and health economic measures. Patients: Women (>18 years of age) with IBS-C according to the Rome II criteria. Methods: Prospective, double blind, placebo controlled, randomised trial. Women with IBS-C either received tegaserod 6 mg twice daily or placebo for one month. Patients with at least a partial response entered a treatment free interval. Upon symptom recurrence, tegaserod treated patients were re-randomised to tegaserod or placebo for an additional month. Primary efficacy variables were response (overall IBS symptoms and abdominal discomfort/pain) to first and repeated treatment. Analysis was by intention to treat. Results: 2660 patients and 1191 patients were randomised for first and repeated treatment respectively. Tegaserod was superior to placebo for each primary efficacy variable (first treatment: 33.7% v 24.2% responders respectively for relief of IBS symptoms and 31.3% v 22.1% for relief of abdominal discomfort/ pain; repeated treatment: 44.9% v 28.7%, and 42.4% v 27.1%, all p,0.0001). Tegaserod was superior to placebo for every secondary efficacy variable (relief of abdominal discomfort/pain, bloating and constipation; stool frequency and consistency). A response to tegaserod was observed within the first treatment week. Tegaserod produced greater satisfaction, work productivity, and improved quality of life than placebo (p,0.05). Conclusion: Tegaserod provides rapid and sustained relief of IBS-C symptoms both during first and repeated treatment.

show abstract

Review article: tegaserod — the global experience

Chey

2004

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Tegaserod is effective in the retreatment of irritable bowel syndrome with constipation (IBS-C)

Cited by 5 publications

References 0 publications

Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: A cost-effectiveness analysis☆

Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: A cost-effectiveness analysis☆

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

Review article: tegaserod — the global experience

Contact Info

Product

Resources

About